Last reviewed · How we verify
NCT03951883
Does Increased Egg Consumption Have Cognitive and Neural Benefits in Food Insecure, At-risk Adolescents?
NA trial testing Increased Egg Consumption in Adolescents With Food Insecurity in 18 participants. Completed in 1 March 2021.
1 March 2021
Quick facts
| Lead sponsor | Texas Tech University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 18 |
| Start date | 1 May 2019 |
| Primary completion | 1 March 2021 |
| Estimated completion | 1 March 2021 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Increased Egg Consumption
- Typical diet
Conditions studied
- Adolescents With Food Insecurity — all drugs for Adolescents With Food Insecurity →
Sponsor
Texas Tech University
Who can join
Adults 13 to 19, any sex, with Adolescents With Food Insecurity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Quality nutrient intake is essential for proper development and well-being of children in all aspects of health, including cognitive development. Eggs are of particular interest based on potential cognitive and neurological benefits due in part to significant concentrations of choline and lutein. While overall, choline and lutein have received considerable attention in the literature in relation to cognition and brain function, most studies involving intake in young adults have had short intervention periods ranging from 90 minutes to 3 days. Food insecurity has been associated with decreased academic performance. Given that populations with food insecurity have limited resources to direct towards nutrition, identifying how a widely available, highly versatile and largely affordable source of nutrients (i.e. eggs) may have favorable impacts on cognitive function and brain function will be valuable in informing public health recommendations in this at-risk population. As such the investigators will examine whether an increased egg consumption dietary prescription can have positive effects on functional activity (i.e. fMRI) during an Eriksen-Flanker task, anatomical changes in the brain (i.e. DTI, MRI), and cognitive abilities as measured by the Stop Signal Reaction Time task, Operation Span task, Raven's Progressive Matrices and the Boston Naming Task.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03951883
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Texas Tech University trials
Trials by the same sponsor.
- NCT06755827 — Pilot Testing a Novel Approach to Pediatric Obesity Treatment · Phase 1, PHASE2 · recruiting
- NCT07239609 — ACT for Individuals With MNCD and Their Care Partners · Phase 1 · not yet recruiting
- NCT06919536 — Controlled Feeding With 24 Hour Recall · completed
- NCT06055322 — Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD · NA · recruiting
- NCT06865196 — Investigating a Brief Virtual Seminar Series for Parents of Teens Ages 13-17 · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03951883 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Texas Tech University
- Last refreshed: 11 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03951883.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing